Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Shuk-Man Ka

Shuk-Man Ka

National Defense Medical Center, Taiwan

Title: Renoprotective effects of xenon on lupus nephritis by inhibiting NLRP3 inflammasome and oxidative stress

Biography

Biography: Shuk-Man Ka

Abstract

Lupus nephritis (LN) is a major complication of systemic lupus erythematosus. Development of a novel molecular pathogenesis-oriented therapeutic remedy preventing progression is clinically warranted. The development of accelerated and severe LN (ASLN) has been attributed to a wide range of pathogenic
pathways, such as overt activation of T and B cells, NLRP3 inflammasome and oxidative stress. Unfortunately, the current treatment of ASLN is insufficient. Therefore, to establish novel yet practical therapeutic agents for ASLN is clinically warranted. Xenon (Xe), a noble gas, has been used as an anesthetic, with very low toxicity. In present study, Xe was used to test its renoprotective effects in an ASLN model induced by repeated injections of lipopolysaccharide to SLE-prone NZB/Wf1 mice. The results showed that (1) Xe significantly ameliorated the proteinuria, hematuria, severe renal lesions and improved renal function; (2) Xe suppressed renal inflammation via blocking of the activation of NLRP3 inflammmasome and NF-ĸB; (3) Xe inhibited renal cells apoptosis via blocking Bax/Bcl-2 mediated apoptotic pathway; (4) Xe decreased mitochondrial injury in macrophage, including mitochondrial ROS generation and mitochondrial DNA release into the cytosol. Our data suggest that Xe alleviated the mouse ASLN model by inhibiting the activation of NLRP3 inflammasome and mitochondrial ROS production. Xe may be useful for the treatment of human ASLN.

Speaker Presentations

Speaker PPTs Click Here